Lantheus Acquires Life Molecular Imaging (Life Molecular) for $350M Upfront

Lantheus Acquires Meilleur Technologies (NAV-4694)

July 15, 2024

Pharmaceuticals

Lantheus Holdings, Inc. announced the acquisition of Meilleur Technologies, Inc., giving Lantheus worldwide exclusive rights to NAV-4694 (F18-flutafuranol), a Phase 3 ß-amyloid PET imaging agent for Alzheimer’s disease. The deal includes an upfront payment plus potential development/commercial milestones and royalties, and the sellers will provide transition and clinical development services following closing.

Lantheus Holdings Acquires Cerveau Technologies

February 6, 2023

Pharmaceuticals

Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.

Lantheus Holdings to Acquire Evergreen Theragnostics for $250 Million Upfront

January 28, 2025

Healthcare Services

Lantheus Holdings has signed a definitive agreement to acquire Evergreen Theragnostics in an all-cash deal with a $250 million upfront payment and up to $752.5 million in development and sales milestones. The acquisition is intended to expand Lantheus into a fully integrated radiopharmaceutical leader by adding Evergreen’s radiopharmaceutical CDMO manufacturing infrastructure and development capabilities, as well as the registrational-stage PET diagnostic agent OCTEVY.

SHINE Technologies Completes Acquisition of Lantheus SPECT Business

January 2, 2026

Healthcare Services

SHINE Technologies completed its acquisition of Lantheus’ SPECT business, including the North Billerica, Massachusetts manufacturing facility and the diagnostic radiopharmaceutical product portfolio. The deal expands SHINE’s nuclear medicine platform with established SPECT production expertise and market relationships, positioning SHINE to strengthen the medical isotope supply chain for diagnostic imaging.

Ariceum Therapeutics Acquires Theragnostics Ltd.

June 1, 2023

Biotechnology

Ariceum Therapeutics has acquired 100% of Theragnostics Ltd., a UK-based developer of radiopharmaceutical diagnostic and therapeutic products, for $2.5 million upfront plus up to $41.5 million of milestone payments. The deal gives Ariceum late preclinical/early clinical PARP inhibitor assets, US FDA‑approved NEPHROSCAN™ (partnered with GE Healthcare) and expanded US operations, strengthening its diagnostic and therapeutic radiopharmaceutical pipeline.

Quest Diagnostics Acquires LifeLabs from OMERS for CAN$1.35B

July 8, 2024

Healthcare Services

Quest Diagnostics has agreed to acquire LifeLabs from Canadian pension fund OMERS for approximately CAN$1.35 billion (approximately USD $985 million), including net debt. LifeLabs will retain its brand, Toronto-area headquarters, and management, and Quest expects the acquisition to expand its diagnostic footprint in Canada while enhancing service offerings and data security.